At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the September 2026 edition.

The IMF team of medical editors has provided overviews of key studies. We encourage you to visit the original journal articles for full details and to deepen your understanding. Check the IMF Newsroom monthly for updates like this one.

In the Journals (Key Myeloma Research in August 2026)

Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

Source

B. Reardon, I. Kerridge, and T. Armytage, “ Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia.” Asia- Pacific Journal of Clinical Oncology (2026): . https://doi.org/10.1111/ajco.70143 August 1, 2026. 

Overview

This retrospective study evaluated real-world treatment patterns between 2018 and 2023 and survival outcomes among patients receiving daratumumab-based therapy in two regional tertiary centers. Most patients received a combination of daratumumab, bortezomib, and dexamethasone (60%, 32). Daratumumab-based combinations were feasible in a regional setting and yielded meaningful clinical outcomes in an older cohort with a high proportion of adverse cytogenetics. 

Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience

Source

An, G., Jin, J., Cai, Z., Jing, H., Fu, C., He, P., … Qiu, L. (2026). Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology, 31(1). https://doi.org/10.1080/16078454.2026.2702681 September 1, 2026. 

Overview

The report describes the safety profile of talquetamab in Chinese patients from MonumenTAL-1, focusing on GPRC5D-associated on-target/off-tumor adverse events (AEs). Adult Chinese patients with heavily pretreated RRMM and measurable disease received subcutaneous talquetamab 0.4 mg/kg once weekly (QW) or 0.8 mg/kg biweekly (Q2W). Supportive management of these AEs without need for dose modification enabled prolonged treatment. 

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting

Source

Henriques Peck O, McCoubrey A, Snowden JA, Wechalekar A, Travers J, Lees JS, et al. Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting. Open Heart. 2026;13:e004240. https://doi.org/10.1136/openhrt-2026-004240 September 1, 2026. 

Overview

The review examined practice-changing MM trials with respect to amyloidosis and cardiovascular disease eligibility criteria, assessment for cardiac amyloidosis, reporting of baseline cardiovascular characteristics and cardiovascular adverse events (CVAE). These limitations may bias safety and efficacy outcomes and reduce trial generalisability. 

Reconstruction-kernel Dependence of Femoral Bone Marrow Attenuation in Whole-body Dual-source Photon-counting CT of Patients with Multiple Myeloma

Source

Huflage H, Scheiner F, Grunz JP, Kunz AS, Feldle P, Müller L, Bley TA, Heidemeier A. Reconstruction-kernel Dependence of Femoral Bone Marrow Attenuation in Whole-body Dual-source Photon-counting CT of Patients with Multiple Myeloma. Acad Radiol. 2026 Sep 1:S1076-6332(26)00680-X. doi: 10.1016/j.acra.2026.08.065. Epub ahead of print. 

Overview

This study aims to investigate how kernel selection influences the femoral bone marrow attenuation in patients with multiple myeloma. This retrospective study included 103 consecutive patients who underwent noncontrast whole-body photon-counting computed tomography (PCCT) for assessment of multiple myeloma. Otherwise, attenuation differences may reflect reconstruction choice rather than changes in marrow composition. 

Multiple Myeloma and Renal Health: Navigating Selected Clinical Complexities

Source

Hussain A, Moniot J L, Sumaya M, et al. (September 01, 2026) Multiple Myeloma and Renal Health: Navigating Selected Clinical Complexities. Cureus 18(9): e115585. doi:10.7759/cureus.115585 September 1, 2026. 

Overview

This review examines the pathophysiology, diagnostic evaluation, pharmacologic management, and pharmacist-led supportive care strategies for MM-related renal dysfunction. Ultimately, collaborative multidisciplinary care involving pharmacists, hematology/oncology specialists, nephrologists, nurses, and patients is necessary to preserve kidney function, reduce treatment-related complications, and improve both renal and overall survival. 

Machine learning-based cuproptosis prognostic signature identifies LDHA as a critical regulator of progression in multiple myeloma

Source

Long, X., Li, G., Li, F. et al. Machine learning-based cuproptosis prognostic signature identifies LDHA as a critical regulator of progression in multiple myeloma. Discov Onc (2026). https://doi.org/10.1007/s12672-026-05869-2 September 1, 2026 

Overview

Ninety-five unique algorithmic combinations were evaluated through machine learning optimization to establish an optimal cuproptosis prognostic signature (CPPS). This study provides a valuable tool for guiding future clinical and personalized treatment approaches for MM. 

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states

Source

Zada, M., Kurilovich, A., Shapira, N. et al. A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states. Nat Genet (2026). https://doi.org/10.1038/s41588-026-02725-5 September 1, 2026. 

Overview

Researchers generated a clinically annotated, population-scale, single-cell atlas of MM from 341 individuals spanning the disease and treatment continuum. FCRL2-targeted chimeric antigen receptor T cells demonstrated antigen-specific activity in vitro and survival benefit in vivo. 

Real-World Efficacy and Safety of Standard-of-Care Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM)

Source

P. Theprungsirikul, R. Wang, S.-H. Chang, et al., “ Real-World Efficacy and Safety of Standard-of-Care Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM),” European Journal of Haematology (2026): 1-11, https://doi.org/10.1111/ejh.70304. September 1, 2026. 

Overview

The study aimed to evaluate the real-world (RW) efficacy and safety of standard-of-care CAR-T versus T-cell engager therapies in relapsed/refractory myeloma (RRMM), to assess utilization, outcomes, and tolerability of these therapies in a RW oncology in the US. This study provides insights on the RW effectiveness of CART versus TCE in the treatment of RRMM; highlights the differences in patient selection, clinical responses, treatment duration, and toxicity profiles. 

Spatial profiling identifies a distinct and topographically defined tumor microenvironment that emerges during multiple myeloma evolution

Source

Marnix Koops, Luca Bertamini, Natalie Papazian, Charlotte Korst, Mátyás János. Budai, Remco M. Hoogenboezem, Mathijs A. Sanders, Bronno van der Holt, Mark van Duin, Annemiek Broijl, Péter Balogh, Sonja Zweegman, Marc HGP. Raaijmakers, Niels W.C.J. van de Donk, Zoltán Kellermayer, Pieter Sonneveld, Tom Cupedo; Spatial profiling identifies a distinct and topographicallydefined tumor microenvironment that emerges during multiple myeloma evolution. Blood Cancer Discov 2026; https://doi.org/10.1158/2643-3230.BCD-26-0080 September 1, 2026. 

Overview

The pathobiology of multiple myeloma is influenced by cells of the bone marrow, but whether tumor support is organized in a spatially-defined tumor microenvironment (TME) remains unclear. Using spatial transcriptomics and imaging mass cytometry, researchers show that myeloma cells initially exist as scattered cells throughout the marrow, yet with disease evolution condense into a spatially-defined TME. 

Do social determinants obscure the genetic contribution to multiple myeloma risk? Brazil as a model for Latin America

Source

Bruna da Silva Oliveira, Cesar Augusto Becher dos Santos, Deisy Morselli Gysi, Caroline Aquino Moreira-Nunes, Carolina Mathias, Daniel Pacheco Bruschi; Do social determinants obscure the genetic contribution to multiple myeloma risk? Brazil as a model for Latin America. Blood Global Hematology 2026; 2 (3): 100131. doi: https://doi.org/10.1016/j.bglo.2026.100131 September 1, 2026. 

Overview

In this context, researchers evaluated the allele frequency of 29 single nucleotide polymorphisms previously associated with thalidomide and bortezomib toxicity and efficacy, comparing data from the 1000 Genomes Project10 with a Brazilian population data set5 (Figure 2; supplemental Table 7). The emergence of initiatives led by organizations such as the Pan American Health Organization and the Health Equity Network of the Americas,13 which aim to develop policies and practices to eliminate health inequities in the region, highlights the pressing need for Latin America to implement health strategies that are responsive to its cultural, social, and demographic diversity. 

Preleukapheresis risk factors for BCMA CAR-T product manufacturing failure

Source

Samantha Sparrow, Allyson Wolcott, Sarah Mott, James Davis, James McCollough, Hira Shaikh, Christopher Strouse; Preleukapheresis risk factors for BCMA CAR-T product manufacturing failure. Blood Immunology & Cellular Therapy 2026; 2 (3): 100068. doi: https://doi.org/10.1016/j.bict.2026.100068 September 1, 2026. 

Overview

Researchers analyzed the relationship between prior therapy exposure and manufacturing outcomes, with a focus on the length of time since last exposure by drug class. Differences in patient/disease characteristics were not associated with manufacturing failure. 

Clinical outcomes of ASCT in multiple myeloma: a study of the Plasma Cell Dyscrasia Working Party of PBMT

Source

Raheel Iftikhar, Danyal Ahmed Ghani, Shahzad Sarwar, Natasha Ali, Nida Anwar, Syed Waqas Bokhari, Saima Humayun, Ayesha Iftikhar, Munira Moosajee, Uzma Zaidi, Usman Ahmad, Bushra Ahsan, Maryam Khan, Aisha Jamal, Salman Naseem Adil, Saad Z. Usmani, Muhammad Ayaz Mir; Clinical outcomes of ASCT in multiple myeloma: a study of the Plasma Cell Dyscrasia Working Party of PBMT. Blood Global Hematology 2026; 2 (3): 100121. doi: https://doi.org/10.1016/j.bglo.2026.100121 September 1, 2026. 

Overview

Multivariate analyses documented superior overall survival (OS) and progression-free survival (PFS) for patients who underwent transplantation in complete response or better and use of melphalan 200 mg/m2 vs 140 mg/m2 conditioning. Efforts should focus on improving diagnostics, optimizing induction regimens, and expanding posttransplant maintenance to maximize survival outcomes in low- and middle-income countries. 

Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma

Source

Su, S., Yan, S., Wu, J. et al. Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma. Stem Cell Rev and Rep (2026). https://doi.org/10.1007/s12015-026-11228-z September 2, 2026. 

Overview

This review synthesizes pivotal trials, real-world cohorts, and translational studies into a risk-adapted framework for longitudinal care. The objective is not to add therapy by default, but to preserve treatment-free remission when observation is safe, intervene before high-risk residual disease becomes organ-threatening, and protect the host and target landscape required for the next effective treatment. 

Jagged-dependent Notch signaling governs extracellular vesicle bioactivity in multiple myeloma

Source

Giannandrea, D., Citro, V., Platonova, N. et al. Jagged-dependent Notch signaling governs extracellular vesicle bioactivity in multiple myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026-03121-y September 2, 2026. 

Overview

Multiple myeloma (MM) is an incurable hematological malignancy characterized by plasma cell expansion and profound remodeling of the bone marrow (BM) niche promoting tumor growth, angiogenesis, osteolytic lesions, and immune modulation, all of which contribute to disease progression. Moreover, JAG2 transcript expression is an independent prognostic biomarker for both overall and progression-free survival, further underscoring the clinical relevance [4]. 

Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells

Source

B. Divsalar, J. Kiani, S. Abroun, and M. Soleimani, “Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells,” APMIS 134, no. 9 (2026): e70256, https://doi.org/10.1111/apm.70256. September 2, 2026. 

Overview

In this study, BCMA-directed CAR-NK-92 cells were generated via lentiviral transduction of a second-generation CAR construct. These findings demonstrate that anti-BCMA CAR-NK-92 cells exhibit potent and selective antimyeloma activity in vitro, supporting CAR-NK-92 cells as an off-the-shelf immunotherapeutic platform for multiple myeloma. 

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance

Source

Pierangela M. R. Sabbattini, Nikolaos Trasanidis, Jason Taslim, Harry Whitwell, Yiming Huang, Valentina S Caputo, Han Leng Ng, Aristeidis Chaidos, Katrina Fordwor-Hepburn, Qizhen Jia, Alexia Katsarou, Maria Atta, Marco Bua, Jose Ros-Soto, Irene Roberts, Niklas Feldhahn, Nicholas Crump, Anastasios Karadimitris; CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance. Blood 2026; blood.2026033534. doi: https://doi.org/10.1182/blood.2026033534 September 2, 2026. 

Overview

The study investigates the role of CXXC1, a core component of the H3K4 methyltransferase complex COMPASS, in the activity of the IKZF1/3-IRF4-MYC regulatory loop. High CXXC1 expression in primary myeloma cells is associated with higher chromatin accessibility, while acute depletion of degron-tagged CXXC1 further validates its role in regulating myeloma cell fitness programs and high-risk transcriptional signatures. 

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and metaanalysis guiding treatment selection

Source

Liang Q, Liu S, Li C, Liang Z, Zhu L, Wang W, et al. BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and metaanalysis guiding treatment selection. Br J Haematol. 2026; 00: 1-11. https://doi.org/10.1111/bjh.70824 September 2, 2026. 

Overview

Bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) or G protein-coupled receptor, class C, group 5, member D (GPRC5D) represent effective options for relapsed or refractory multiple myeloma (RRMM), yet direct comparative evidence remains limited. The response appeared to be influenced primarily by treatment history. 

Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience

Source

Alberto-López, L. J., Melchor-Melo, O. E., Gómez-Cabrera, M. Á., Velasco- Padilla, J. R., Ramírez-García, J. P., Anaya-Valdés, P. A., … Ruiz-Argüelles, G. J. (2026). Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience. Hematology, 31(1). https://doi.org/10.1080/16078454.2026.2727801 September 2, 2026. 

Overview

The study evaluated whether longitudinal follow-up based exclusively on serologic monitoring can predict survival outcomes in a real-world cohort of patients with MM. This retrospective single-center study included 88 consecutive patients diagnosed with MM between 1999 and 2024. In resource-limited settings or centers where serial bone marrow-based MRD assessment is impractical, comprehensive serologic monitoring offers a feasible, non-invasive alternative for longitudinal disease evaluation. 

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study

Source

Paula Rodriguez-Otero, Daniel Morillo, Anita D'Souza, Donna Reece, Niels van de Donk, Ajai Chari, Bhagirathbhai Dholaria, K. Martin Kortüm, Maria-Victoria Mateos, John T. Mckay, Laura Rosiñol, Anna Sureda, Ralph Wäsch, Manisha Bhutani, Katja C Weisel, Nizar J Bahlis, Deeksha Vishwamitra, Sheri Skerget, Kalpana K Bakshi, Yue Guo, Weili Sun, Jenna D. Goldberg, Tara Stephenson, Thomas J Prior, Lien Vandenberk, Sangmin Lee, M. Damiette Smit, Raluca I. Verona, Albert Oriol, Amrita Krishnan; Teclistamab and Daratumumab Immune- Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study. Blood Adv 2026; bloodadvances.2026020648. doi: https://doi.org/10.1182/bloodadvances.2026020648 September 2, 2026. 

Overview

The study evaluated the safety and efficacy of teclistamab combined with the anti-CD38 monoclonal antibody daratumumab in the phase 1b TRIMM-2 study. In conclusion, the fully immune-based combination of weight-based RP2D teclistamab plus daratumumab demonstrated deep and durable responses, with a well-characterized safety profile highlight the importance of infection management, including early immunoglobulin replacement. 

A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study

Source

Song Jin, Zhaohui Liao, Shuang Yan, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Fang Tang, Ziling Zhu, Depei Wu, Nishanthan Rajakumaraswamy, Yi Luo, Daijing Yuan, Hua Jiang, Zonghai Li, Chengcheng Fu; A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study. Blood 2026; 148 (10): 1251-1262. doi: https://doi.org/10.1182/blood.2025032112 September 3, 2026 

Overview

Host-versus-graft reaction (HVGR) is a major challenge in allogeneic chimeric antigen receptor (CAR) T-cell therapy. These results suggest that CAR-NKG2A technology may overcome HVGR, especially in patients with elevated NKG2A expression on NK cells. 

Patient-Reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-Body Injector vs Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma

Source

Gurdeep Parmar, Marcelo Capra, Vania Hungria, Fernanda Salles Seguro, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Ivan Špička, Jiří Minařík, Herlander Marques, Ludĕk Pour, Jana Mihályová, Junichiro Yuda, Kazutaka Sunami, Graça Esteves, Cynthia Chmielewski, Christine Soufflet, Disa Yu, Erin Comerford, Florence Suzan, Paul Cordero, Rick Zhang, Hang Quach, Patient- Reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-Body Injector vs Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.08.019. September 3, 2026. 

Overview

The phase 2 IZALCO study (NCT05704049) demonstrated comparable efficacy, safety, and pharmacokinetics for subcutaneous (SC) isatuximab administered via an on-body injector (Isa SC OBI) vs manual injection in combination with carfilzomib-dexamethasone in relapsed/refractory multiple myeloma. The study evaluated patient-reported outcomes (PROs) in 74 adults and experiences of 19 healthcare providers (HCPs) from IZALCO. These findings support Isa SC OBI as the preferred administration method for patients and HCPs. 

Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry

Source

Kylee H. Maclachlan, Marios Papadimitriou, Patrick Blaney, Linda B. Baughn, Tala Shekarkhand, Alexandra M. Poos, Bachisio Ziccheddu, Hongwei Tang, Huihuang Yan, Benjamin Diamond, Yanming Zhang, Robert Cimera, Ahmet Dogan, Dylan Gagler, Eileen Boyle, Malin Hultcrantz, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Carlyn Tan, Elizabeth E. Brown, Lara Winterkorn, Timothy Chu, Zoe Steinsnyder, Zalman Vaksman, Faith E. Davies, Neha Korde, Ola Landgren, Marc S. Raab, Alexander M. Lesokhin, Nicolas Robine, Niels Weinhold, Saad Z. Usmani, Francesco Maura, Gareth J. Morgan; Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry. Blood Cancer Discov 1 September 2026; 7 (5): 742-758. https://doi.org/10.1158/2643-3230.BCD-25-0259 

Overview

To comprehensively investigate somatic drivers in relation to inherited genetics in multiple myeloma, researchers combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Finally, researchers demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes. 

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Source

Maximilian Merz, Tomas Jelinek, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian von Tresckow, Marcel Teichert, Uta Margareta Demel, Antonia Busse, Marie Christine Wesener, Tobias A.W. Holderried, Friederike Schmitz, Friedrich-Linus Rößiger, Fabian Müller, Michele Hoffmann, Friedrich Stölzel, Natalia Tovar, Ben-Niklas Baermann, Martin Stork, Alexandra Jungova, Jiri Minarik, Jakub Radocha, Ivan Spicka, Ludek Pour, Polona Novak, Klara Slajpah, Karla Rener, Ulrich Keller, Stephan Bohl, David Fandrei, Patrick Born, Vladan Vučinić, Nicolaus Kröger, Irene Strassl, Natalie Schub, Roman Hájek, Matjaž Sever, Carlos Fernández de Larrea, Nico Gagelmann; Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood Cancer Discov 1 September 2026; 7 (5): 697-710. https://doi.org/10.1158/2643-3230.BCD-25-0461 

Overview

Researchers explored single or consecutive chimeric antigen receptor (CAR) T and bispecific antibody (BsAb) treatment modalities as correlates of clinical outcomes, by complementary bias-correction analysis of a retrospective multicenter study of 640 patients with relapsed/refractory multiple myeloma. These data support a treatment paradigm that prioritizes timely and equitable access to both modalities, recognizing that logistic barriers to CAR T availability may themselves contribute to outcome disparities. 

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

Source

Wesener MC, Demel UM, Pabst T, Teipel R, Albici A-M, von Tresckow B, Teichert M, Boquoi A, Holderried T, Schmitz F, Müller F, Rößiger F-L, Hoffmann M, Schub N, Tovar N, Oliver-Caldes A, Kröger N, Baermann B-N, Bohl S, Fandrei D, Vucinic V, Strassl I, Stölzel F, de Larrea CF, Keller U, Busse A, Merz M, Gagelmann N. Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma. Haematologica; https://doi.org/10.3324/haematol.2026.301082 [Early view]. September 3, 2026. 

Overview

Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Selection of highly active, immune-compatible bridging regimens can meaningfully improve pre-infusion disease control and post-infusion outcomes without compromising safety. 

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience

Source

Botta C, Rizzuto A, Speciale M, Gigliotta E, Corsale AM, Romano F, Mussotto I, Aquilina C, Romano A, Biondo M, Tofacchi E, Di Simone M, Sciortino M, Brucato F, Guercio G, Di Caro M, Merenda A, Vasta S, Scazzone C, Bivona G, Calò V, La Manna MP, Caccamo N, Dieli F, Siragusa S, Meraviglia S. Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a singlecenter experience. Haematologica; https://doi.org/10.3324/haematol.2026.300864 [Early view]. September 3, 2026. 

Overview

The study evaluated the feasibility and clinical utility of two CE-IVD-approved EuroFlow tubes for minimal residual disease (MRD) detection in a real-world clinical setting, and investigated the relationship between bone marrow (BM) immune profiles and disease outcomes. Our findings confirm the feasibility and prognostic relevance of NGF-based MRD detection using standardized commercial panels, and highlight the potential of immune profiling to provide additional biological insights into MRD dynamics in multiple myeloma. 

Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma

Source

Lonial S, Richardson PG, Ferron-Brady G, Carreño F, Papathanasiou T, Ho YL, McKeown A, Brock K, Roy-Ghanta S, Melhem M, Mukhopadhyay P, Abdullah HA, Mateos M-V, Dimopoulos MA. Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma. Haematologica; https://doi.org/10.3324/haematol.2026.301229 [Early view]. September 3, 2026. 

Overview

Exposure-response analyses using Cycle 1 exposures (data from the DREAMM-6, DREAMM-7, and DREAMM-8 trials) and BVd dosing regimen simulation (using a previously developed and validated framework) were performed to support benefit-risk analysis of belantamab mafodotin dosing strategies to improve outcomes. Altogether, a belantamab mafodotin starting dose of 2.5 mg/kg in RRMM is important to achieve deeper response and outweighs modest improvements in tolerability from a 1.9 mg/kg starting dose. 

FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy

Source

Hamm, A.F., Vorwerk, J., Merz, M.M. et al. FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy. Pilot Feasibility Stud 12, 130 (2026). https://doi.org/10.1186/s40814-026- 01914-7 September 3, 2026. 

Overview

While efficacy has been explored in breast cancer patients, there is a lack of data for haematological patients, including MM. FASTINA will evaluate whether TRE is feasible and safe in selected MM patients and whether there is a hypothesis-generating signal for improved treatment response, informing the design of a subsequent phase II trial. 

Dynamic Prediction of Survival Outcomes in Multiple Myeloma

Source

Quek, K., Lee, C. H., Zhang, Y., McClure, B. J., Chen, R., Scott, H. S., Vandyke, K., Zannettino, A. C. W., & Kok, C. H. (2026). Dynamic Prediction of Survival Outcomes in Multiple Myeloma. Cancers, 18(17), 2864. https://doi.org/10.3390/cancers18172864 September 3, 2026. 

Overview

The model was validated in five independent diagnostic cohorts (n = 1255) and in two independent treatment and relapsed/refractory cohorts (n = 319). The framework supports longitudinal patient monitoring and may inform trial enrichment strategies and closer surveillance for high-risk subpopulations. 

Second autologous hematopoietic stem cell transplantation in multiple myeloma

Source

Kakkar, D., Mohan, V., Dalal, H., Sanyal, S., & Naithani, R. (2026). Second autologous hematopoietic stem cell transplantation in multiple myeloma. Indian Journal of Cancer https://doi.org/10.4103/ijc.ijc_50_26 September 3, 2026. 

Overview

High-dose melphalan followed by autologous stem cell transplantation (ASCT) is standard in multiple myeloma (MM), but relapse remains inevitable. This retrospective study included six patients with relapsed MM who underwent ASCT2 between 2012 and 2025. ASCT2 is a feasible salvage strategy in selected Indian patients with MM, yielding favorable outcomes with acceptable toxicity. 

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

Source

Perron, N., Foster, K., Mouhieddine, T.H. et al. Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026- 03092-0 September 3, 2026. 

Overview

Researchers profiled the bone marrow (BM) immune compartment in a phase II trial of nivolumab with lenalidomide and low-dose dexamethasone (NivoRd) in high-risk smoldering MM (HR-SMM [6]) using paired pre- and post-treatment imaging mass cytometry (IMC) and single-cell RNA sequencing (scRNAseq). The gain of that coordination differed sharply by group: a linear mixed-effects ANCOVA showed a PC PD-L1 × Group interaction (LRT χ² = 17.2, p = 3.3 × 10⁻⁵), with P/NR macrophages acquiring twice the PD-L1 increment per unit of plasma-cell PD-L1 (slope +0.92 vs +0.45), indicating an amplified macrophage PD-L1 program in P/NR independent of tumor PD-L1 burden. 

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients

Source

Ntanasis-Stathopoulos I, Nikolaou P-E, Filippatos C, Miliotis M, Kostopoulos IV, Bakouros P, Makridakis M, Liacos C-I, Nikolopoulos K, Laidou S, Chatzidimitriou A, Frantzi M, Kastritis E, Fotiou D, Gavriatopoulou M, Vlahou A, Hatzigeorgiou AG, Tsitsilonis O, Dimopoulos MA, Terpos E. Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients. Haematologica; https://doi.org/10.3324/haematol.2026.301208 [Early view]. September 3, 2026. 

Overview

Semaphorin (Sema) 4D, activin-A, and periostin ELISA, LEGENDplex™ Human Bone Metabolism Panel and proteomic analysis for novel biomarker identification were conducted in 71 consecutive samples from NDMM patients. Genomic analyses identified variants associated with inferior PFS, including HLA-DRB5 (c.300_306delinsCGGG) and HLA-DQB1 (c.317_319delinsCGG). 

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma

Source

Mahmoud R. Gaballa, Kelley Julian, Aimaz Afrough, Doris K. Hansen, Utkarsh Goel, Andre De Menezes Silva Corraes, Danai Dima, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Lindsay Fogel, Shahzad Raza, Rahul Banerjee, Saurabh S. Zanwar, Oren Pasvolsky, Aishwarya Sannareddy, Azra Borogovac, James Davis, Kimberly Green, Noa Biran, Eli Zolotov, Megan Herr, Leyla Shune, Evguenia Ouchveridze, Shaun DeJarnette, Shebli Atrash, Christopher Ferreri, Tiffany Richards, Muhammad Bilal Abid, Susan Bal, Hossam M. Ali, Jing Christine Ye, Shambavi Richard, Gurbakhash Kaur, Kenneth Shain, Omar Castaneda-Puglianini, Ken Harada, Gabriel De Benjamin Podvin, Holly Lee, Rémi Tilmont, Gauthier Decool, Doriane Cavalieri, Hélène Demarquette, Nicolas Gower, Morgane Nudel, Emmanuelle Bourgeois, Daniela Robu, Sabine Tricot, Inès Arib, Victoria Cacheux, Aurélie Caillault-Venet, Claude Preudhomme, Nicolas Duployez, Thierry Facon, Paola Neri, Nizar Bahlis, Salomon Manier; TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma. Blood Adv 2026; 10 (17): 5934-5937. doi: https://doi.org/10.1182/bloodadvances.2026020518 September 8, 2026. 

Overview

Researchers report the use of targeted next-generation sequencing panel that enabled the identification of BCMA alterations, including mutations affecting the extracellular domain of BCMA, that informed treatment decisions in 5 patients with MM who developed clinical relapse after BCMA-directed therapy. In conclusion, The observations highlight the clinical value of TNFRSF17 sequencing in routine practice for guiding treatment decisions by capturing tumor-intrinsic genetic resistance that emerges under therapeutic pressure. 

Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan

Source

Yuasa, A., Nagano, M., Kamei, Y., Hatsuyama, K., Matsuda, H., Hlavacek, P., … Suzuki, K. (2026). Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan. Journal of Medical Economics, 29(1), 2295-2309. https://doi.org/10.1080/13696998.2026.2730069 September 8, 2026. 

Overview

The study evaluated the cost-effectiveness of elranatamab versus physician’s choice of treatment (PCT) for patients with triple class exposed multiple myeloma in Japan. A cost-effectiveness analysis was conducted comparing elranatamab with PCT using a partitioned survival model with three health states from the Japanese public healthcare payer perspective. From the healthcare payer perspective, elranatamab was cost-effective versus PCT in the base case and scenario analyses, with ICERs consistently below commonly accepted thresholds in Japan; contingent on the unanchored MAIC and long-term extrapolation, this should be interpreted with caution. 

Next Generation Sequencing in the Diagnosis of Multiple Myeloma

Source

Ikram EL Fazazi, Hajar Ihlal, Amal Ouskri, Samira Nmer, Angela Washenko, Hinde EL Mouhi, Meriame Abbassi, Mohamed Ahakoud, Laila Bouguenouch, Rhizlane Berrady, Karim Ouldim, Mohammed El-Azami-El-Idrissi. Next Generation Sequencing in the Diagnosis of Multiple Myeloma. Front. Biosci. (Schol Ed) 2026, 18(3), 44690. https://doi.org/10.31083/FBS44690 (registering DOI) September 4, 2026. 

Overview

This review summarizes current evidence on the application of NGS technologies, including whole-exome sequencing, whole-genome sequencing, and targeted gene panels-in the diagnosis, prognostic assessment, and monitoring of MM. The growing body of evidence supporting NGSbased MRD as a strong predictor of relapse and clinical outcome underscores its potential to refine treatment monitoring and guide therapeutic decision-making. 

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma

Source

Cheng, W., Gaggero, S., Hasan Bou Issa, L. et al. Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma. Biomark Res 14, 119 (2026). https://doi.org/10.1186/s40364- 026-00992-2 September 5, 2026. 

Overview

The study examined 21 daratumamab-lenalidomide (DR) pre-treatment samples from the IFM2017-03 phase 3 trial using single-cell and bulk multiomics approaches to identify determinants of response. The study underscores an NF-κB-associated inflammatory axis underlying poor DR response and suggests that targeting inflammatory pathways a potential therapeutic avenue warranting further investigation. 

Construction and Validation of a Progression-Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification

Source

Y. Rao, S. Li, A. Yu, et al., “Construction and Validation of a Progression-Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification,” Cancer Medicine 15, no. 9 (2026): e72077, https://doi.org/10.1002/cam4.72077. September 6, 2026. 

Overview

The study investigated the clinical characteristics of newly diagnosed multiple myeloma (NDMM) patients with 1q21 gain/amplification (1q21+), construct and validate a progression-free survival (PFS) prediction model, and explore the clinical implications of model-based risk stratification. researchers retrospectively analyzed 186 newly diagnosed multiple myeloma patients with 1q21+ treated between 2018 and 2024. The HLBP model showed promising preliminary performance for predicting progression-free survival (PFS) in patients with 1q21+ NDMM and may provide an exploratory framework for individualized risk stratification. 

Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

Source

K. Wang, C. Zhao, J. Shi, et al., “Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma,” Cancer Science (2026): 1-15, https://doi.org/10.1111/cas.70523. September 6, 2026. 

Overview

Researchers developed a 12-gene immune-related gene signature (IRGS) using an integrative machine-learning framework and evaluated its prognostic performance across multiple MM cohorts. Collectively, these findings define the IRGS as a complementary immune-associated molecular biomarker for prognostic stratification in MM and provide a framework linking prognosis with multicellular transcriptional context, somatic mutational characteristics, and candidate therapeutic vulnerabilities. 

A machine-learning-derived online prediction model based on inflammatory and nutritional composite indicators for acute kidney injury in sepsis patients with multiple myeloma

Source

Zhang Q, Xin Q and Guo H (2026) A machine-learning-derived online prediction model based on inflammatory and nutritional composite indicators for acute kidney injury in sepsis patients with multiple myeloma. Front. Nutr. 13:1874801. doi: 10.3389/fnut.2026.1874801 September 6, 2026 

Overview

Acute kidney injury (AKI) frequently complicates sepsis in patients with multiple myeloma (MM), yet no validated predictive tool integrates the inflammatory and nutritional disturbances specific to this dual-disease population. The integrated workflow from feature selection to web-based deployment further illustrates the feasibility and value of translating complex machine learning models into accessible point-of-care applications for this high-risk population. 

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma

Source

Yokoyama, D., Minakata, D., Fujiwara, S. ichiro, Honda, S., Tominaga, R., Noguchi, A., … Kanda, Y. (2026). MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma. Leukemia & Lymphoma, 1-13. https://doi.org/10.1080/10428194.2026.2723847 September 6, 2026. 

Overview

This single-institution retrospective study evaluated a measurable residual disease (MRD)- guided induction intensification strategy in transplant-eligible patients with newly diagnosed multiple myeloma treated in the anti-CD38 antibody era. This MRD-adapted strategy was feasible, achieved deep responses, and preserved mobilization, but high-risk disease remained prone to relapse, supporting posttransplant intensification. 

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma

Source

Li, Y., Shi, L., Yan, W. et al. Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026-03133-8 September 7, 2026 

Overview

The study investigated whether circulating tumor cells (CTC) refine CGS and enable longitudinal residual disease monitoring. Overall, CTC-integrated CGS supports minimally invasive baseline risk stratification and longitudinal disease monitoring. 

Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratory measurements, and treatment history

Source

Shangru Jia, Artem Lysenko, Keith A Boroevich, Alok Sharma, Tatsuhiko Tsunoda, Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratory measurements, and treatment history, Briefings in Bioinformatics, Volume 27, Issue 5, September 2026, bbag475, https://doi.org/10.1093/bib/bbag475 September 7, 2026. 

Overview

Researchers developed a dynamic multimodal framework that predicts residual overall survival from observation windows of 1-18 months post-diagnosis. These findings support the potential of dynamic multimodal modeling for longitudinal prognostic assessment in MM. 

PTTG1-driven self-amplifying loop with SP1 and ENO1 promotes IRF4-mediated myeloma progression and bone destruction

Source

Liu, R., Huang, Y., Fang, Z. et al. PTTG1-driven self-amplifying loop with SP1 and ENO1 promotes IRF4-mediated myeloma progression and bone destruction. Cell Death Dis (2026). https://doi.org/10.1038/s41419-026-09210-1 September 7, 2026. 

Overview

Multiple myeloma (MM) is a neoplastic disorder of plasma cells within the hematopoietic system and is characterized by osteolytic lesions. The use of blocking peptides to interfere with this interaction demonstrates significant efficacy in curbing myeloma progression and osteolytic lesions, offering a promising avenue for clinical intervention. 

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Source

Kaiser MF, Phillip RH, Brown SR, Holroyd A, Ferris E, de Tute RM, Roberts S, Clayton L, Bowles K, Garg M, Lokare A, Messiou C, Houlston RS, Jackson G, Cook G, Owen RG, Drayson MT, Pratt G, Hall A, Jenner MW. Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5year follow-up of a multicentre, externally controlled, phase 2 trial. Lancet Oncol. 2026 Sep 7:S1470-2045(26)00286-X. doi: 10.1016/S1470-2045(26)00286-X. Epub ahead of print. 

Overview

The report describes the 5-year follow-up of survival outcomes across molecular subgroups. The multicentre, externally controlled, phase 2 OPTIMUM trial was conducted at 22 centres in the UK and enrolled patients aged 18 or older with newly diagnosed high-risk multiple myeloma or plasma cell leukaemia, measurable disease according to IMWG criteria, up to two previous induction cycles, and an Eastern Cooperative Oncology Group Performance Status of 2 or less. OPTIMUM shows sustained progression-free survival and overall survival improvement with risk-stratified extended therapy, supporting implementation of molecular diagnostics and tailored treatment in patients with newly diagnosed high-risk multiple myeloma. 

Revision and complication rates after total joint arthroplasty in patients with monoclonal gammopathy of undetermined significance and multiple myeloma

Source

Kodra, J.D., Schweinert, A., Memon, A.A. et al. Revision and complication rates after total joint arthroplasty in patients with monoclonal gammopathy of undetermined significance and multiple myeloma. International Orthopaedics (SICOT) (2026). https://doi.org/10.1007/s00264-026-07024-6 September 8, 2026. 

Overview

To characterize the complication profiles and implant survivorship of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) patients undergoing primary hip and knee total joint arthroplasty (TJA). A retrospective analysis was conducted of MM and MGUS patients who underwent TJA at our tertiary academic center from 2005-2023. Although there was no significant difference in revision risk between MM and MGUS, the small sample size and heterogeneity limit direct comparisons. 

A study of ubiquitination and liquid-liquid phase separation related genes yields uba1 as a primary candidate biomarker for a role in multiple myeloma

Source

Chen, C., Li, Y., Chen, Z. et al. A study of ubiquitination and liquid-liquid phase separation related genes yields uba1 as a primary candidate biomarker for a role in multiple myeloma. BMC Cancer (2026). https://doi.org/10.1186/s12885-026- 16899-y September 8, 2026. 

Overview

Ubiquitination and liquid-liquid phase separation has been reported to be closely related to the development and occurrence of tumors, but its role in multiple myeloma (MM) remains unexplored. For the first time, based on ubiquitination and liquid-liquid phase separation prognosis related genes (ULLPSRGs), consistent clustering analysis and prognostic difference analysis were conducted, and a prognostic model was constructed through multivariate Cox regression. Our signature can provide clinicians with prognostic predictions and help guide the treatment of patients with MM. 

Adapting a mental health program for people with multiple myeloma and smouldering myeloma: a consumer-informed feasibility study

Source

Tuckey, N., Iasiello, M., Cantley, M. et al. Adapting a mental health program for people with multiple myeloma and smouldering myeloma: a consumer-informed feasibility study. Support Care Cancer 34, 937 (2026). https://doi.org/10.1007/s00520- 026-11163-2 September 8, 2026. 

Overview

Researchers report on a mixed-method pilot study to evaluate the suitability of an existing mental health program for people living with incurable blood cancer, multiple myeloma, and precursor form, smouldering multiple myeloma. Consumer involvement in mental health interventions is recognised as essential to producing research that is relevant, acceptable, and ultimately more effective. 

Prioritizing quality of life over thrombotic risk: Thromboprophylaxis in multiple myeloma - an interview study

Source

Codreanu C, Siezen TD, Roeloffzen WWH, Kooistra HAM, Meijer K. Prioritizing quality of life over thrombotic risk: Thromboprophylaxis in multiple myeloma - an interview study. Journal of Oncology Pharmacy Practice. 2026;0(0). doi:10.1177/10781552261485966 September 8, 2026. 

Overview

This qualitative interview study aims to identify which factors influence the choice of thromboprophylaxis in MM. Fifteen Dutch physicians experienced in treating patients with MM were interviewed about the factors influencing their choice of thromboprophylaxis. Most physicians agreed on the need to increase awareness of the high venous thromboembolism (VTE) risk in patients with MM. 

Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria

Source

Domingo-González A, Cannata-Ortiz P, Fernández-Prado R, Velasco-Valdazo A, Menéndez-Cuevas M, Martos R, Pavía Pascual L, Prieto Pareja E, Naya D, García Corral B, Mahíllo-Fernández I, Llamas Sillero P, Solán L and Askari E (2026) Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria. Front. Med. 13:1902202. doi: 10.3389/fmed.2026.1902202 September 8, 2026. 

Overview

Current recommendations for hematologic response (HemR) assessment in monoclonal gammopathies of renal significance (MGRS) are based on the monoclonal immunoglobulin (MIg) component responsible for renal damage. Comparing hematological and renal response across studies is complex due to the heterogeneity in assessment methods, type of MGRS measured, and follow-up time. 

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia

Source

Avila, Adriana Rossi, Hamza Hassan, Larry D. Anderson, Peter M. Voorhees, Jack Khouri, Surbhi Sidana, Andrew J. Portuguese, Murali Janakiram, Hans C. Lee, Yi Lin, Ariel Grajales-Cruz, Krina K. Patel, Douglas W. Sborov; Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia. Blood Adv 2026; 10 (17): 5938-5950. doi: https://doi.org/10.1182/bloodadvances.2026020826 September 8, 2026. 

Overview

The study evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary plasma cell leukemia (PCL) across 15 academic centers, categorized as active (≥5% circulating plasma cells within 30 days before BsAb initiation) or historical. Participants This multicenter, retrospective study included data from 15 academic centers in the United States that participated in the MM Immunotherapy Consortium. Finally, the development of effective combination regimens could be pursued to overcome resistance in this biologically aggressive population. 

IFM 2026 Recommendations for First-Line Treatment of Newly Diagnosed Multiple Myeloma

Source

Aurore Perrot, Salomon Manier, Cyrille Hulin, Hélène Demarquette, Arthur Bobin, Laurent Frenzel, Lionel Karlin, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf, Jérôme Lambert, Jill Corre, Thierry Facon, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, IFM 2026 Recommendations for First-Line Treatment of Newly Diagnosed Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.09.002. September 9, 2026. 

Overview

Finally, researchers summarize ongoing trials investigating T-cell-redirecting immunotherapies (CAR-T cells and bispecific antibodies) as replacements for, or additions to, autologous stem cell transplant (ASCT) and maintenance therapy, which may further reshape the first-line treatment paradigm in the coming years. researchers discuss the role of measurable residual disease and NGSbased high-risk myeloma definition across both populations, and position these recommendations relative to the 2025 EHA-EMN evidence-based guidelines. 

Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003)

Source

Fei Xiao, Liru Wang, Fei Li, Fang Wang, Yuping Zhong, Xiaoyan Qu, Chunkang Chang, Zhenyu Li, Yang Liu, Xuelin Dou, Lei Wen, Nan Peng, Jin Lu, Jian Hou, Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003), Med, 2026, 101293, ISSN 2666-6340, https://doi.org/10.1016/j.medj.2026.101293. September 9, 2026. 

Overview

POM-MM-003 study compared pomalidomide-bortezomib-dexamethasone (PVd) with Vd in newly diagnosed multiple myeloma (NDMM) patients with RI. POM-MM-003 was open-label, randomized, phase II study done at eight centers in China (ClinicalTrials.gov: NCT05432414). PVd may represent a potential treatment option for this patient population. 

A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment

Source

M. Liu, Y. Jian, H. Zhou, et al., “A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment,” Cancer Medicine 15, no. 9 (2026): e72054, https://doi.org/10.1002/cam4.72054. September 9, 2026. 

Overview

This multicenter, retrospective study aimed to develop and validate a practical nomogram for predicting early death (< 12 months) using readily accessible clinical parameters. This validated model provides the first practical tool for early mortality risk stratification in MM patients with RI, enabling clinicians to identify high-risk patients who may benefit from more intensive interventions. 

Routine Laboratory-Based Machine Learning for Discriminating Multiple Myeloma from Clinical Mimickers: Development and Internal Validation of a Diagnostic Prediction Model

Source

Erdoğdu, B., Gül, D., Aylı, B. I., Karadeniz, M., Yıldırım, M., & Cömert, M. (2026). Routine Laboratory-Based Machine Learning for Discriminating Multiple Myeloma from Clinical Mimickers: Development and Internal Validation of a Diagnostic Prediction Model. Diagnostics, 16(18), 2928. https://doi.org/10.3390/diagnostics16182928 September 9, 2026. 

Overview

The aim of this study was to develop and internally validate statistical and machine learning (ML) models that discriminate MM from clinically similar conditions using exclusively routine laboratory parameters. These findings support the potential of maching-learning-based analysis of routine laboratory data as a practical clinical decision support tool for earlier MM recognition and optimized diagnostic workflows, particularly in settings where access to specialized testing may be delayed. 

Establishing barriers and enablers to nurse-enabled, subcutaneous therapy self-administration programs for myeloma patients: A qualitative, descriptive study

Source

Hayley Beer, Lisa Guccione, Amit Khot, Simon Harrison, Meinir Krishnasamy, Establishing barriers and enablers to nurse-enabled, subcutaneous therapy selfadministration programs for myeloma patients: A qualitative, descriptive study, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.09.007. September 9, 2026. 

Overview

This study aims to identify barriers and enablers to the implementation of nurse-enabled subcutaneous therapy self-administration programs (NESTSPs) for patients with multiple myeloma (MM) and explore strategies to support implementation across diverse healthcare settings. A qualitative, interpretive description study was conducted with patients, carers, health professionals, and policy makers. While regulatory and funding barriers remain significant, strong patient-centred benefits and alignment with healthcare priorities support wider adoption. 

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making

Source

Abdul-Hamid Bazarbachi et al. Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making. J Clin Oncol 0, JCO-26-00545 DOI:10.1200/JCO-26-00545 September 10, 2026 

Overview

Cereblon's identification as a druggable E3 ligase substrate receptor created the mechanistic path to next-generation modulators, whereas widespread frontline lenalidomide exposure created the clinical need for scalable oral agents active in IMiD-refractory, triple-class-exposed disease. Immunomodulatory drugs (IMiDs) have fundamentally reshaped multiple myeloma therapy, extending survival and establishing durable backbones across induction, relapse, and maintenance. 

Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma

Source

Jerald D. Noble, Barbara C. Peixoto, Meghan A. Menges, Julieta Abraham- Miranda, Constanza Savid-Frontera, William Sawyer, Vasu D. Sorathia, Luis A. Cuadrado Delgado, Salvatore A. Corallo, Julia C. Llanos, Emily C. Merritt, Gabe de Avila, Omar A. Castaneda Puglianini, Hien Liu, Melissa Alsina, Taiga Nishihori, Kenneth H. Shain, Ariosto S. Silva, Rachid C. Baz, Brandon J. Blue, Ariel F. Grajales-Cruz, Doris K. Hansen, John L. Cleveland, Fabiana Perna, Conor C. Lynch, Jennifer M. Binning, Reginald M. Atkins, Xiaofei Song, Frederick L. Locke, Ciara L. Freeman; Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. Blood 2026; 148 (11): 1409-1422. doi: https://doi.org/10.1182/blood.2025031843 September 10, 2026. 

Overview

These analyses revealed that a transcriptional program in CD4 CAR-T cells that led to durable responses is characterized by NF-κB signaling, prosurvival circuits, tonic/chemokine signaling, and elevated CAR transgene expression. The results support that NF-κB in the ide-cel product marks a signaling axis affecting CAR-T function and that NF-κB activity represents a global marker of T-cell fitness present before CAR-T manufacture. 

Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study

Source

Shragai T, Lavi N, Vaxman I, Gatt ME, Chubar E, Ganzel C, Magen H, Luttwak E, Mittelman M, Trestman S, Lebel E, Saban R, Vainstein V, Zuckerman T, Horowitz N, Tzoran I, Horesh N, Lowenton-Spier N, Melamed N, Pereg I, Avivi I, Cohen YC. Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study. Haematologica; https://doi.org/10.3324/haematol.2026.301067 [Early view]. September 10, 2026. 

Overview

This is a phase II, investigator-initiated, open-label, single-arm, prospective, multicenter study evaluating all-oral Ixazomib-pomalidomidedexamethasone (IPd) regimen for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) patients. To conclude, the all-oral IPd regimen for TCE RRMM patients showed high response rates and a manageable safety profile, in a cohort enriched with triple-class refractory (TCR), elderly and frail patients. (NCT04790474). 

Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials

Source

Osama M, Khan MH, Tahir A, Hussain A, Iftikhar A, Ali A, Khan S, Bilal Hassan M, Alam I, Khan Z, Afridi A, Ebad Ur Rehman M, Gul A, Thada PK. Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials. Ther Adv Hematol. 2026 Sep 11;17:20406207261489040. doi: 10.1177/20406207261489040. 

Overview

This study aims to compare the efficacy and safety of daratumumab-based quadruplet therapy regimens with standard triplet therapy regimens in newly diagnosed multiple myeloma (NDMM) patients. The meta-analysis shows higher efficacy yet higher adverse events in Daratumumab-based quadruplet therapy for NDMM patients (transplant-eligible and transplant-ineligible). 

Prognostic value of a combined systemic immune-inflammation index and prognostic nutritional index score for risk stratification in newly diagnosed multiple myeloma: a retrospective cohort study

Source

Wang, X., Yao, Y. & Feng, Y. Prognostic value of a combined systemic immuneinflammation index and prognostic nutritional index score for risk stratification in newly diagnosed multiple myeloma: a retrospective cohort study. Ann Hematol (2026). https://doi.org/10.1007/s00277-026-07267-8 September 11, 2026 

Overview

A pretreatment score integrating the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) was developed and internally validated for progression-free survival (PFS) and overall survival (OS) risk stratification. The SII-PNI score may provide complementary prognostic information and help refine risk stratification beyond conventional staging. 

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Source

Nadeem, O., Cordas dos Santos, D.M., Magidson, S. et al. Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04642-w September 11, 2026. 

Overview

In the randomized phase 2 ImmunoPRISM trial, researchers compared fixed-duration teclistamab with lenalidomide-dexamethasone (Rd) in high-risk smoldering multiple myeloma (HR-SMM). Toxicities in the teclistamab arm included grades 1-2 cytokine release syndrome, no neurotoxicity, and no increase in grade 3 infections compared to Rd (20% versus 21%). 

Multiple Myeloma-Derived Cellular Lipids Enhance Targeting and Efficacy of Nanoliposome Formulations In Vitro

Source

Amorin, M., Tran, C., Park, E., Rodriguez Flores, P. L., Smullen, W., Daley, P., Pham, K., Barve, S., & Campbell, R. B. (2026). Multiple Myeloma-Derived Cellular Lipids Enhance Targeting and Efficacy of Nanoliposome Formulations In Vitro. International Journal of Molecular Sciences, 27(18), 8155. https://doi.org/10.3390/ijms27188155 September 12, 2026. 

Overview

researchers now report on the use of cellular lipid extracts (LEs) originating from two different human multiple myeloma (target) cell lines, RPMI 8226 and NCI H929, to develop RPMI 8226 LEand NCI H929 LE-modified nanoliposomes, respectively. The LE-modified nanoliposomes stably incorporated various cytotoxic agents, demonstrating novel formulation characteristics and cell-interaction profiles. 

The relationship between inflammation and multiple myeloma: insights into alterations and prognostic value

Source

Tóth, T., Alizadeh, H., Polgár, B. et al. The relationship between inflammation and multiple myeloma: insights into alterations and prognostic value. GeroScience (2026). https://doi.org/10.1007/s11357-026-02494-3 September 12, 2026 

Overview

MM patients exhibited elevated IFN-γ, IL-10, MCP-1 and reduced IL-17A, TGF-α compared to controls. Integrating these biomarkers into risk models may improve stratification and guide personalized therapy. 

The Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study

Source

Zhang, X., Li, X., Liu, J., Huang, B., Gu, J., Chen, M., Kuang, L., & Li, J. (2026). The Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study. Cancers, 18(18), 2958. https://doi.org/10.3390/cancers18182958 September 12, 2026. 

Overview

Researchers retrospectively analysed 335 newly diagnosed MM patients who underwent upfront autologous stem cell transplant (ASCT). Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT. 

AI-driven structural analysis clarifies novel TNFRSF17 variants of uncertain significance as candidate resistance mechanisms to BCMA-targeted immunotherapies in multiple myeloma

Source

Ricardo Ahrens, Behnam Yousefi, Nora Constanze Laubach, Marietta Truger, Torsten Haferlach, Sven Heins, Raphael Teipel, Constantine Mitsiades, Evangelos Papadopoulos, Kyra Ahrens, Piet Sonnemann, Maximilian Al-Bazaz, Jule Artzenroth, Lisa Leypoldt, Christoph Schaefers, Maximilian Christopeit, Moritz Kaune, Leo Rasche, Carsten Bokemeyer, Stefan Bonn, Katja Weisel, Winfried Alsdorf, AI-driven structural analysis clarifies novel TNFRSF17 variants of uncertain significance as candidate resistance mechanisms to BCMA-targeted immunotherapies in multiple myeloma, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.09.010. September 14, 2026. 

Overview

Researchers developed a structure-based framework to generate agent-level hypotheses of therapeutic binding after BCMA-directed therapy. Researchers analyzed a cohort of 59 patients with r/r MM who underwent routine WGS at progression after BCMA-directed therapy at 2 German tertiary cancer centers; 25 samples were evaluable, and 4 non-truncating TNFRSF17 VUS were identified. Direct disulfide-cysteine alterations were associated with broader predicted structural perturbation, non-cysteine variants more often showed agent-dependent effects. 

Supportive Care in Multiple Myeloma: Evidence-Based Recommendations from the Intergroupe Francophone du Myélome (IFM)

Source

Laurent Frenzel, Pascal Godmer, Alexis Talbot, Cécile Sonntag, Stéphanie Harel, Thomas Chalopin, Salomon Manier, Cyrille Hulin, Thierry Facon, Lionel Karlin, Jill Corre, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, Olivier Decaux, Bertrand Arnulf, Chanaz Louni, Mohamad Mohty, Aurore Perrot, Emilie Chalayer, Murielle Roussel, Supportive Care in Multiple Myeloma: Evidence- Based Recommendations from the Intergroupe Francophone du Myélome (IFM), Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.09.008. September 14, 2026. 

Overview

Multiple myeloma (MM) is a largely incurable plasma cell malignancy in which disease- and treatment-related complications substantially impair quality of life and survival, making supportive care a central determinant of outcome. By consolidating these seven domains into a single framework applicable across all lines of therapy, from first-line treatment to relapsed/refractory disease, this review offers a pragmatic reference intended to standardize and improve supportive care and, ultimately, patient outcomes and health-related quality of life (HRQoL) in MM. 

REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma - a US claims-based case-control study

Source

Davies, F.E., Faiman, B., Beer, H. et al. REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma-a US claimsbased case-control study. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01609-5 September 14, 2026 

Overview

This retrospective, 1:1 matched case-control study used U.S. administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes. 

Circulating tumor plasma cells quantification in newly diagnosed transplant-ineligible real-world multiple myeloma patients: Comparison of single-platform flow cytometry versus next-generation flow

Source

Saraci, E., Larocca, A., Ria, R., Mangiacavalli, S., Benevolo, G., Giuliani, N., Zambello, R., Belotti, A., Rizzello, I., Falcone, A. P., Vincelli, I. D., Michieli, M., Ronconi, S., Tosi, P., Siez, M. M., Allegra, A., Cavalli, M. M., Scaldaferri, M., Fedele, I., … D'Agostino, M. (2026). Circulating tumor plasma cells quantification in newly diagnosed transplant-ineligible real-world multiple myeloma patients: Comparison of single-platform flow cytometry versus next-generation flow. Cytometry Part B: Clinical Cytometry, 1-8. https://doi.org/10.1002/cyto.b.70068 September 14, 2026. 

Overview

In this study researchers compare head-to-head two flow cytometry (FC) techniques [single-platform FC versus Next Generation Flow (NGF)] to measure circulating tumor cell (CTC) levels in newly diagnosed multiple myeloma (NDMM) patients. In conclusion, NGF demonstrated higher sensitivity than single-platform FC to detect CTCs at diagnosis in MM patients. 

Outcomes of stereotactic radiosurgery for spine multiple myeloma - a systematic review

Source

Izhar, M., Hori, Y.S., Kattaa, A.H. et al. Outcomes of stereotactic radiosurgery for spine multiple myeloma-a systematic review. Neurosurg Rev 49, 565 (2026). https://doi.org/10.1007/s10143-026-04493-6 September 14, 2026. 

Overview

This systematic review evaluated the clinical outcomes and safety profile of  stereotactic radiosurgery (SRS) for spinal MM. SRS appears to provide excellent local control and meaningful pain and neurological improvement in patients with spinal MM, with acceptable toxicity profiles. 

Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system

Source

He, X., Chen, G., Zhan, Z., & Li, Z. (2026). Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology, 31(1). https://doi.org/10.1080/16078454.2026.2730041 September 15, 2026 

Overview

The study evaluated adverse event (AE) signals, temporal patterns, and clinical priorities associated with teclistamab using the FDA Adverse Event Reporting System (FAERS). The safety profile broadly aligned with clinical trial data, but novel signals and sepsis-related fatality highlighted clinically important risks. 

Outcomes in patients with multiple myeloma and renal impairment undergoing autologous hematopoietic cell transplantation

Source

Martins, L., Ribeiro, C., Gasparini, J. et al. Outcomes in patients with multiple myeloma and renal impairment undergoing autologous hematopoietic cell transplantation. Ann Hematol (2026). https://doi.org/10.1007/s00277-026-07152-4 September 15, 2026. 

Overview

This retrospective study evaluated AHCT outcomes in 53 MM patients with RI (creatinine > 2 mg/dL or clearance < 40 mL/min) treated at a public hospital in Brazil between 2010 and 2023. AHCT in this setting was associated with high NRM and frequent intensive care utilization, but survival was comparable to prior studies. 

Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions

Source

Gang Wang, Hanlin Gao, Tianyi Xie, Fuming Zi, Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions, International Immunopharmacology, Volume 185, 2026, 116996, ISSN 1567-5769, https://doi.org/10.1016/j.intimp.2026.116996. September 15, 2026. 

Overview

Previous research has predominantly emphasized clonal evolution and adaptive immune dysfunction, whereas the contribution of innate immunity to MM initiation and progression has been comparatively underappreciated. A deeper mechanistic understanding of innate immune dysregulation may not only refine current immunotherapeutic strategies but also inspire novel therapeutic paradigms, ultimately improving long-term disease control in MM. 

Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort

Source

Korkmaz, G., Ceran, F., Dagdas, S., Akgun, S., Kızılkaya, K., Ceylan, A., Ozturk, F., Aydın, M. S., Isleyen, E., Erdogan Yon, M. E., & Ozet, G. (2026). Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long- Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort. Journal of Clinical Medicine, 15(18), 7184. https://doi.org/10.3390/jcm15187184 September 15, 2026. 

Overview

The study evaluated the long-term efficacy and safety of salvage autologous stem cell transplant (ASCT) in a real-world single-center cohort. Salvage ASCT was associated with durable disease control and acceptable transplantation-related outcomes in this carefully selected cohort. 

The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma

Source

Yue, C., Huang, B.-H., Qi, L., Zhang, X.-D., & Li, J. (2026). The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma. International Journal of Molecular Sciences, 27(18), 8239. https://doi.org/10.3390/ijms27188239 September 15, 2026 

Overview

Publicly available MM transcriptomic datasets and the MMRF-CoMMpass cohort were analyzed to evaluate  NAD (P)-dependent steroid dehydrogenase-like protein (NSDHL) expression and its clinical relevance. Our data reveal a novel NSDHL/c-Myc/PKM2 regulatory axis that drives glycolytic reprogramming and MM cell proliferation, highlighting NSDHL as a potential prognostic biomarker and therapeutic target in MM. 

A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections

Source

F. Zhu and H. Wang, “A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections,” Cancer Medicine 15, no. 9 (2026): e72270, https://doi.org/10.1002/cam4.72270. September 15, 2026. 

Overview

This study describes trends in the ageand sex-specific burden of MM in China from 1990 to 2023, including incidence, prevalence, mortality, and disability-adjusted life years (DALYs); projects sex-specific incidence to 2050; and compares findings globally. Using the Global Burden of Disease (GBD) 2023 database, researchers extracted data on MM in China and globally from 1990 to 2023. Priority public health strategies for prevention and control are essential to address this growing public health issue. 

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial

Source

Schaefers, C., Khandanpour, C., Hänel, M. et al. Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-16905-3 September 16, 2026. 

Overview

Multiple myeloma (MM) is a widely incurable B-cell malignancy that predominantly affects older adults, representing 10% of hematologic cancers. The BELI(E)VE trial (NCT05853965) is a German investigator-initiated, prospective, multicenter, open-label phase I/IIa study designed to evaluate the combination of belantamab mafodotin and venetoclax, with or without dexamethasone, in patients with relapsed or refractory multiple myeloma (RRMM) with ≥1 prior treatment line and t(11;14) translocation. The translational component, examining circulating tumor cells and mitochondrial activity, may identify mechanisms of resistance and response, guiding future personalized therapeutic strategies. 

American Society of Hematology 2026 guidelines for diagnosis of iron deficiency

Source

Jacquelyn M Powers, Ming Yeong Lim, Maureen O. Achebe, Imo J Akpan, Michael Auerbach, Megan C Brown, Maria Paula Cardenas, Caroline Cromwell, Thomas G. DeLoughery, Robert E. Fleming, Martina Fraga, George Goshua, Paula D. James, Adam K Lewkowitz, Jori Ellen May, Grace Nnadozie, Frances Ogunnaya, Guillermo J. Ruiz-Arguelles, Michelle Sholzberg, Layla Van Doren, Angela C. Weyand, Michelle Paula Zeller, Muayad Azzam, Ali Choaib, Qais Hamarsha, Hassan Kawtharany, Jana Khawandi, Reem A. Mustafa; American Society of Hematology 2026 guidelines for diagnosis of iron deficiency. Blood Adv 2026; bloodadvances.2025015950. doi: https://doi.org/10.1182/bloodadvances.2025015950 September 16, 2026. 

Overview

The University of Kansas Health System supported the guideline-development process, including performing systematic evidence reviews on the prevalence of iron deficiency across populations and studies to inform diagnostic thresholds up to July 2025. The panel prioritized clinical questions according to clinical impact and high-risk populations. 

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma

Source

Iryna Dekhtiarenko, Jan Attig, Iva Lelios, Stephan Schmeing, Carmen SM Yong, Wolfgang Jacob, Emilio Yángüez, Tamara Hüsser, Llucia Albertí Servera, Inga Clausen, Hans J. Grote, Cláudia S. Ferreira, Hans-Joachim Helms, Cristina Santini, Emilie Schindler, Sylvia Herter, Marina Bacac, Carmelo Carlo-Stella, Anna Caroline Hasselbalch, Salomon Manier, Antonio Pinto, Paolo Corradini, Cyrille Hulin, Sung-Soo Yoon, Rakesh Popat, Simon J. Harrison, Martin Weisser, Ann-Marie E. Bröske; T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma. Blood Adv 2026; bloodadvances.2026020503. doi: https://doi.org/10.1182/bloodadvances.2026020503 September 16, 2026. 

Overview

This phase 1 study (NCT04557150) investigated mode of action and resistance mechanisms of forimtamig, a novel GPRC5DxCD3 TCB. The results highlight that forimtamig treatment optimization may be possible by boosting T cell numbers over NK cells, targeting tumor intrinsic resistance mechanisms or individualized dosing approach. 

Cutaneous Toxicities of Anti-GPRC5D Bispecific Antibodies for Multiple Myeloma: Retrospective Study

Source

A. Gotor-Rivera, A. Blanco-Sánchez, B. Rodríguez-Sánchez, J. Martínez-López, P. L. Ortiz-Romero, and F. Tous-Romero, “Cutaneous Toxicities of Anti-GPRC5D Bispecific Antibodies for Multiple Myeloma: Retrospective Study,” The Journal of Dermatology (2026): 1-9, https://doi.org/10.1111/1346-8138.70497. September 16, 2026. 

Overview

Researchers aim to describe the real-world burden of cutaneous toxicities. These findings expand the clinicopathological spectrum of talquetamab toxicity and highlight the importance of interdisciplinary care. 

Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy

Source

Gembillo, G., Soraci, L., Lo Cicero, L., Terzo, C., Casuscelli, C., Cuzzola, F., Sudano, F., Ricca, M. F., Scapellato, M., Messina, R., La Spada, A., Sharma, A., & Santoro, D. (2026). Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy. Journal of Clinical Medicine, 15(18), 7211. https://doi.org/10.3390/jcm15187211 September 16, 2026. 

Overview

Medium-cutoff membranes, polymethylmethacrylate adsorptive dialyzers, and hemodiafiltration with endogenous reinfusion have achieved substantial serum free light-chain (sFLC) reduction with less albumin loss in small uncontrolled series, without any randomized comparison against conventional dialysis. Conventional high-flux hemodialysis combined with prompt antimyeloma therapy is therefore the evidence-based standard kidney-replacement modality when dialysis is indicated; the patient subsets in which a time-limited enhanced-removal strategy might still be tested are proposed as hypotheses for prospective trials, without validated thresholds. 

Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma

Source

Kenshi Suzuki, Hiroshi Kosugi, Toshiro Ito, Yasushi Takamatsu, Peter M Voorhees, S Vincent Rajkumar, Miku Ito, Chika Sakai, Marimo Takahashi, Tomohiko Nakatogawa, Robyn Dennis, Robin Carson, Meletios A Dimopoulos, Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma, Japanese Journal of Clinical Oncology, 2026;, hyag146, https://doi.org/10.1093/jjco/hyag146 September 16, 2026. 

Overview

In the global phase 3 AQUILA trial, daratumumab monotherapy was associated with a significantly lower risk of progression to active multiple myeloma or death than active monitoring in patients with high-risk smoldering multiple myeloma without unexpected safety concerns (NCT03301220). Researchers report a subgroup analysis of Japanese patients from the trial. These findings may provide useful information for determining treatment options in Japanese patients with high-risk smoldering multiple myeloma. 

Mapping the scientific research on mesenchymal stromal cells and multiple myeloma: a bibliometric analysis

Source

Wu, X., Jiang, L., Geng, Z. et al. Mapping the scientific research on mesenchymal stromal cells and multiple myeloma: a bibliometric analysis. Discov Onc (2026). https://doi.org/10.1007/s12672-026-05964-4 September 17, 2026 

Overview

This study aimed to map the global scientific research landscape concerning mesenchymal stromal cells (MSCs) and multiple myeloma (MM) over the past two decades (2000-2025) using bibliometric analysis to identify publication trends, key contributors, research themes, and evolving hotspots. Overcoming MSC-mediated immunosuppression and promoting bone repair represent critical future research priorities for improving MM therapies. 

Impact of Melphalan Conditioning Dose and Infused CD34⁺ Cell Dose on Engraftment Kinetics, Transfusion Requirements, and Early Transplant Outcomes Following Autologous Stem Cell Transplantation for Multiple Myeloma

Source

Chowdhury, S., Chakrapani, A., Mukherjee, S. et al. Impact of Melphalan Conditioning Dose and Infused CD34⁺ Cell Dose on Engraftment Kinetics, Transfusion Requirements, and Early Transplant Outcomes Following Autologous Stem Cell Transplantation for Multiple Myeloma. Indian J Hematol Blood Transfus (2026). https://doi.org/10.1007/s12288-026-02587-1 September 17, 2026 

Overview

This study compared the effects of standard-dose (Mel200) and reduced-dose (Mel140) melphalan conditioning on engraftment kinetics, transfusion requirements, and early transplant outcomes, while evaluating the impact of infused CD34⁺ cell dose in autologous HSCT for multiple myeloma. Optimizing stem cell mobilization and achieving an adequate CD34⁺ cell dose may have a greater impact on early transplant outcomes than conditioning intensity alone. 

Diagnostic and prognostic value of bone metabolism biomarkers in newly diagnosed plasma cell myeloma

Source

Korpysz, M., Bogdanowicz-Żeleźniak, A., Kowalska-Kępczyńska, A. et al. Diagnostic and prognostic value of bone metabolism biomarkers in newly diagnosed plasma cell myeloma. Sci Rep (2026). https://doi.org/10.1038/s41598-026- 70071-x September 17, 2026 

Overview

The study aimed to evaluated the diagnostic and prognostic value of markers of bone metabolism, i.e. activin A, Dkk-1, GDF-15, β-CTX and sclerostin in patients with PCM. Dkk-1 concentration showed the highest diagnostic accuracy for bone lesion detection in PCM; however, given the study’s retrospective design and limited longitudinal data, the clinical relevance of this finding, including its prognostic implications, requires confirmation in prospective studies. 

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis

Source

Cowan AJ, Gras L, Cassano R, Atsuta Y, Baaij L, Bass F, Bazarbachi A, Bekadja MA, Clesham K, Dreger P, D’Souza A, Estrada-Merly N, Goh AS, Iida M, Hayden PJ, Kawamura K, Ko B-S, Koster L, Liam C, Mian H, McCurdy A, Ortiz CAF, Hamad N, McLornan DP, Lv M, Mizuno S, Srivastava A, Quessar A, Riva E, Saber W, Snowden J, Takamatsu H, Tsai XC-H, Verburgh E, Wah HK, Neumann D, Sureda A, Aljurf M, Koh MBC, Galeano S, Kodera Y, Rondelli D, Niederwieser DW, Garderet L. Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis. Haematologica; https://doi.org/10.3324/haematol.2026.301244 [Early view]. September 17, 2026. 

Overview

The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. Maintenance with lenalidomide, and to a lesser extend thalidomide and bortezomib resulted in improved OS as compared to no-maintenance in all depths of response prior to AHCT. 

PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma

Source

Anaïs Schavgoulidze, Jian Cui, Jessica Encinas Mayoral, Vanessa Favasuli, Srikanth Talluri, Sabrina Maheo, Chloé Cerutti, Masood Shammas, Daniel Primo, Carmen Vicente, Marta Larrayoz, José A. Martínez-Climent, Kenneth C. Anderson, Anil Aktas-Samur, Mehmet Kemal Samur, Hervé Avet-Loiseau, Jill Corre, Nikhil C. Munshi, Mariateresa Fulciniti; PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma. Blood 2026; 148 (12): 1559-1571. doi: https://doi.org/10.1182/blood.2026033819 September 17, 2026 

Overview

Deletion of chromosome 17p [del(17p)] is among the most adverse cytogenetic abnormalities in multiple myeloma (MM). Collectively, our findings nominate protein kinase membrane-associated tyrosine/threonine, or PKMYT1, as an actionable target and support PKMYT1 inhibition as a biomarker-driven therapeutic strategy for patients with del(17p) or TP53-deficient MM. 

Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis

Source

Al-Momany HT, Kaylani DZ, Abuhashem O, Nofal AA, Saeed AE, Younis O, Alkuttob LA. Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Curr Probl Cancer. 2026 Sep 18;65:101343. doi: 10.1016/j.currproblcancer.2026.101343. Epub ahead of print. 

Overview

Despite advances in treatments multiple myeloma remains a therapeutically challenging disease. Researchers conducted a systematic review and meta-analysis according to PRISMA guidelines, searching major databases from inception through November 2025. Prospective biomarker-stratified trials are needed to optimize BCMA-targeting sequences and identify patients most likely to benefit. 

Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products

Source

Blumenberg V, June KB, Birocchi F, Escobar G, Graham C, Fan Y, et al. Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products. Journal for ImmunoTherapy of Cancer. 2026;14:e016839. https://doi.org/10.1136/jitc- 2026-016839 September 18, 2026. 

Overview

The effect for 4-1BB CARs observed here cannot be assumed to hold for CD28-based products.16 The study has several limitations: researchers compared the two clinically deployed configurations as units and did not isolate the contribution of the individual elements; the promoter effect (MND vs EF1α), the presence of WPRE and the difference in vector length. Although MND-WPRE gave higher titers, transduction rates and vector copy numbers (VCN), it conferred inferior tumor control in vivo at matched VCN.

Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999-2024

Source

Ali, M.E., Ferrari, F., Hafeez, A.S. et al. Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999-2024. Cancer Causes Control 37, 162 (2026). https://doi.org/10.1007/s10552-026-02253-x September 18, 2026. 

Overview

The study evaluated national MM mortality trends from 1999-2024 and projected trajectories through 2034, stratified by sex, age, race/ethnicity, census region, urbanization, and place of death. MM-related deaths were identified from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database using ICD-10 code C90.0 from 1999- 2024. Reducing these disparities will require not only continued therapeutic advances but also equitable access to care, earlier diagnosis, and improved representation of underserved populations in clinical research. 

SEI1 complex silences p53 to drive myeloma progression

Source

Rui Chen, Rui Liu, Zhihong Fang, Daoyan Yang, Zou Li, Yuan Li, Yuan Li, Shurong Liu, Qi Liu, Yanqi Chao, Chong Wang, Huan Liu, SEI1 complex silences p53 to drive myeloma progression, iScience, Volume 29, Issue 9, 2026, 117300, ISSN 2589-0042, https://doi.org/10.1016/j.isci.2026.117300. September 18, 2026. 

Overview

To address this, researchers investigated the molecular mechanisms driving myeloma progression and identified a pathogenic axis involving SEI1. The results demonstrated that SEI1 expression increases during myeloma progression. 

Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry

Source

Han, J., Liu, S. H., Arsang-Jang, S., Xu, Z., Rentscher, K. E., Mathison, A. J., Tschannen, M., Sun, F., Auer, P. L., Kerns, S., Hari, P., Dhakal, B., Janz, S., Jin, V. X., Urrutia, R., D’souza, A., & Dong, J. (2026). Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry. Cells, 15(19), 1722. https://doi.org/10.3390/cells15191722 September 21, 2026. 

Overview

Because leukocyte telomere length (LTL) has been associated with MM risk and prognosis, and the longer LTL generally observed in healthy AA individuals relative to EA individuals appears attenuated or reversed in MM [22,23,24], researchers evaluated a DNA methylation-based estimator of telomere length (DNAmTL). Combined interpretation of the genomic and DNA methylation results suggested potential thematic overlap involving growth and survival signaling, cellular stress responses, DNA damage and repair, apoptosis, and transcriptional regulation; however, this overlap was not evaluated through formal multi-omics analysis. 

Exploring the psychological impact and healthcare experiences of patients living with triple class refractory multiple myeloma: an interpretative phenomenological analysis study

Source

Ali N, Kuttschreuter L, Quinn S, et al. Exploring the psychological impact and healthcare experiences of patients living with triple class refractory multiple myeloma: an interpretative phenomenological analysis study, BMJ Open 2026;16:e108269. doi: 10.1136/bmjopen-2025-108269 September 21, 2026. 

Overview

While no cure is available, treatments aim to control the disease and place patients into remission. Likewise, patient access to informative materials and practical tools to support engagement in informed decision-making, specifically around treatments and clinical trials, needs to be more routinely offered and made available. 

Inducing oxidative stress by targeting the cholesterol biosynthesis pathway augments the efficacy of bortezomib in multiple myeloma

Source

Chunfan Li, Fuqiang Wang, Hongwei Peng, Meng Chen, Yafang Pu, Xiang Lin, Shuai Wang, Fei Li, Zhimin Gu, Inducing oxidative stress by targeting the cholesterol biosynthesis pathway augments the efficacy of bortezomib in multiple myeloma, Free Radical Biology and Medicine, 2026, ISSN 0891-5849, https://doi.org/10.1016/j.freeradbiomed.2026.09.019. September 21, 2026. 

Overview

Researchers identify a cholesterol biosynthesis-dependent antioxidant mechanism that shields MM cells from bortezomib-induced generation of reactive oxygen species (ROS). Collectively, our findings identify that MM cells resist therapy-induced ROS by accumulating 7-DHC through activation of cholesterol biosynthesis, and provide preclinical evidence for repurposing statins to augment the efficacy of bortezomib therapy. 

Reduced Pathogen-Specific T Cell Response With BCMA-Targeted T Cell-Engaging Therapy to Multiple Myeloma

Source

I. Steiro, S. S. Tryggestad, E. S. Hess, et al. “Reduced Pathogen-Specific T Cell Response With BCMA-Targeted T Cell-Engaging Therapy to Multiple Myeloma.” eJHaem 7, no. 5 (2026): e70388. https://doi.org/10.1002/jha2.70388 September 21, 2026. 

Overview

Bispecific antibody (BsAb) treatment can lead to increased infections in myeloma patients. T cells cultured with a BCMA-BiTEs and HMCLs killed myeloma cells, but showed reduced numbers of pathogen-specific IFNγ+ CD8+ T cells. 

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial

Source

Rees MJ, Lasica M, Kalff A, Low M, Harrup R, Lai HC, et al. Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial. Br J Haematol. 2026; 00: 1-11. https://doi.org/10.1111/bjh.70851 September 22, 2026. 

Overview

SeaLAND (ALLG MM23, ACTRN12620000291987) was a randomized, open-label phase III study evaluating low-dose weekly selinexor (40 mg) plus lenalidomide (selinexor-R) versus lenalidomide alone (R) as post-transplant maintenance therapy for newly diagnosed, transplant-eligible multiple myeloma. Selinexor-R maintenance cannot be recommended for the general myeloma population; researchers did not observe a benefit among high-risk disease. 

An Ex Vivo 3D Co-Culture Model of the Bone Marrow Niche Better Predicts Clinically Relevant Epigenetic Target Modulation to Improve Immunotherapy in Multiple Myeloma

Source

Greil, C., Jung, J., Felthaus, J., Wider, D., Engelhardt, M., & Wäsch, R. (2026). An Ex Vivo 3D Co-Culture Model of the Bone Marrow Niche Better Predicts Clinically Relevant Epigenetic Target Modulation to Improve Immunotherapy in Multiple Myeloma. Cancers, 18(19), 3093. https://doi.org/10.3390/cancers18193093 September 22, 2026. 

Overview

In the last decade, treatment options for multiple myeloma have increased remarkably, including antibodies or CAR-T cells targeting myeloma surface markers with unprecedented efficacy. Epigenetically induced CD38 upregulation to enhance the effect of anti-CD38 antibodies does not appear to be clinically relevant when using an optimized preclinical model. 

Outpatient Step-Up Dosing of Teclistamab and Talquetamab in Relapsed or Refractory

Source

Kunal Shah, Paul Forrest, Ananya Garg, Pranav Kolluru, David Kaminetzky, Gareth J Morgan, Marc Braunstein, Oscar Lahoud, Faith E Davies, Outpatient Step-Up Dosing of Teclistamab and Talquetamab in Relapsed or Refractory, Leukemia Research, 2026, 108318, ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2026.108318. September 22, 2026. 

Overview

Bispecific T-cell-engaging antibodies against BCMA and GPRC5D demonstrate high efficacy in relapsed/refractory multiple myeloma (RRMM) but are associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), traditionally prompting inpatient monitoring when commencing therapy. Researchers conducted a single-center retrospective study evaluating outpatient step-up dosing (SUD) of teclistamab or talquetamab in adults with RRMM. Toxicities occur early and are manageable with structured monitoring, supporting outpatient delivery in appropriately selected patients. 

Real World Outcomes and Factors Influencing Outcomes in Young Multiple Myeloma Patients: Single Center Experience in India

Source

Saha, S., Yadav, S., Mamlekar, H. et al. Real World Outcomes and Factors Influencing Outcomes in Young Multiple Myeloma Patients: Single Center Experience in India. Indian J Hematol Blood Transfus (2026). https://doi.org/10.1007/s12288- 026-02591-5 September 22, 2026. 

Overview

Hence, researchers aimed to evaluate the baseline characteristics and long term outcomes of these patients. researchers had very few patients undergoing early autologous HSCT and hence researchers could not assess the impact of HSCT on outcomes. 

The gut microbiome in multiple myeloma: from disease evolution to therapeutic modulation

Source

Cosyns, J., Faict, S., De Bruyne, E. et al. The gut microbiome in multiple myeloma: from disease evolution to therapeutic modulation. Cell Commun Signal (2026). https://doi.org/10.1186/s12964-026-03243-x September 22, 2026. 

Overview

In this review, researchers summarize current knowledge on the role of the microbiome in MM pathogenesis and examine how widely used MM therapeutics affect the gut microbiome (GM). Researchers further explore how microbial composition modulates clinical outcomes of MM treatments and assess the potential of GM-targeted strategies to improve therapeutic efficacy. 

Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma

Source

Masanori Toho, Rikako Tabata, Daisuke Ikeda, Atsushi Uehara, Hajime Sakuma, Kosuke Shima, Daichi Terunuma, Kazuki Nagao, Naoya Fukuda, Fuminari Fujii, Kentaro Narita, Masami Takeuchi, Hiroyuki Takamatsu, Kosei Matsue; Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma. Blood 2026; blood.2026033768. doi: https://doi.org/10.1182/blood.2026033768 September 22, 2026. 

Overview

In patients with complete datasets, Principal Component Analysis (PCA) and unsupervised clustering were used to classify patients into four phenotypes based on two factors: physical tumor volume (based on bone marrow plasma cell percentage, MRI-total diffusion volume, and PET-metabolic tumor volume) and sBCMA levels. This multimodal classification provides a rational framework for risk stratification. 

RNA-binding protein CIRBP mediates PKM2 intron retention to negatively regulate multiple myeloma progression and macrophage alternative activation

Source

Shen, J., Zhu, L., Yang, R. et al. RNA-binding protein CIRBP mediates PKM2 intron retention to negatively regulate multiple myeloma progression and macrophage alternative activation. Commun Biol (2026). https://doi.org/10.1038/s42003-026-10902-9 September 22, 2026. 

Overview

In this study, publicly available single-cell RNA sequencing data, MM cell lines, and an in vivo xenograft model are utilized to assess the biological significance of cold-inducible RNA binding protein (CIRBP) in MM. These findings support the notion of CIRBP as a candidate tumor suppressor in MM and unveil a post-transcriptional regulatory mechanism governing PKM2-mediated macrophage plasticity. 

Teclistamab Response and Relapse-Related Immune Correlates in the MajesTEC-1 China Cohort

Source

Hongmei Xu, Feng Wang, Deeksha Vishwamitra, Han Yang, Cuc Davis, Rengasamy Boominathan, Dianna Wu, Zhuolu Niu, Yang Song, Juanjuan Song, Hongye Chen, Natalia A Quijano Cardé, Katherine Chastain, Ting Niu, Weijun Fu, Juan Du, Raluca I Verona, Michael Gormley, Christopher Chiu, Ricardo Attar, Longen Zhou, Teclistamab Responseand Relapse-Related Immune Correlates in the MajesTEC-1 China Cohort, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.09.014. September 22, 2026. 

Overview

Researchers evaluated baseline and longitudinal immune profiles in the China cohort to identify immune drivers and potential biomarkers associated with teclistamab response/relapse. Patients with ≥3 prior lines of therapy and triple-class exposed RRMM received teclistamab 1.5 mg/kg weekly after step-up dosing; patients could switch to less frequent dosing with sustained complete response or better. Greater baseline immune fitness, increased early T-cell activation, and lower inflammation/tumor burden were associated with teclistamab response and longer PFS, while T-cell dysfunction was implicated in relapse. 

Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

Source

Nishimura, N., Brown, S., Samorodnitsky, S. et al. Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01621-9 September 22, 2026. 

Overview

The study evaluated stem cell autograft  (AG) minimal residual disease (MRD) using multiparameter flow cytometry to determine its prognostic value for ASCT outcomes. These findings support AG MRD as a prognostic parameter for survival following ASCT in NDMM. 

Evolution of real-world frontline treatment patterns in multiple myeloma

Source

Alexander Lazzaro, Kaelyn Nannini, Cenk Yildirim, Linden Huhmann, John M. Culnan, June K. Corrigan, Danne Elbers, Nhan V. Do, Mary Brophy, Nikhil Munshi, Nathanael R. Fillmore, Camille V. Edwards; Evolution of real-world frontline treatment patterns in multiple myeloma. Blood Adv 2026; 10 (18): 6278- 6288. doi: https://doi.org/10.1182/bloodadvances.2026019843 September 22, 2026. 

Overview

Researchers analyzed overall survival by treatment regimen, diagnosis era, and sociodemographic features. Outcomes continue to improve across treatment eras, although follow-up in the most recent cohort is limited and longterm survival remains incompletely characterized. 

Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c-Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1

Source

Zhang E, Zhang T, Xu J, Zhang Y, Cui J, Li X, Xu J, Zhang T, Jia H, Lin Z, Xu L, Guo D, Huang H. Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c- Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1. Cell Signal. 2026 Sep 19;149:112895. doi: 10.1016/j.cellsig.2026.112895. Epub ahead of print. 

Overview

Accumulating evidence has highlighted the significant role of LEN in MM treatment; however, to date, no studies have investigated its potential efficacy in the ferroptosis pathway of MM and the underlying mechanisms. In conclusion, this study is the first to demonstrate that LEN suppresses MM by inducing ferroptosis via FTH1-dependent iron homeostasis, suggesting that the ferroptosis induced by the c-Maf/USP7/FTH1 signaling pathway during LEN treatment is a novel mechanism underlying its antitumor activity. 

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities

Source

Zeng Z, Lu J, Shang J, You H, Wang Q, Wen L, et al. Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities. Br J Haematol. 2026; 00: 1-14. https://doi.org/10.1111/bjh.70817 September 19, 2026. 

Overview

In this integrated Single Nucleotide Polymorphism (SNP-array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression-free survival (PFS, p = 0.00037), outperforming other metrics. Autologous haematopoietic stem cell transplantation (AHSCT) benefit is restricted to low-risk hyperdiploidy (HRD) with higher ploidy. 

Psychometric evaluation of the PROMIS® Medication Adherence Scale among patients prescribed oral anticancer medication for multiple myeloma

Source

Belcher, S.M., Scott, P., Sereika, S.M. et al. Psychometric evaluation of the PROMIS® Medication Adherence Scale among patients prescribed oral anticancer medication for multiple myeloma. J Patient Rep Outcomes (2026). https://doi.org/10.1186/s41687-026-01204-z September 19, 2026. 

Overview

Medication adherence influences health outcomes, but valid, reliable measures assessing self-reported medication adherence are limited. Evidence supports the feasibility of longitudinal oral anticancer medication adherence assessment monitoring using PROMIS® Medication Adherence Scale (PMAS). 

The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program

Source

Herrera, K., Mitra, S., Sun, Y. et al. The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program. Nat Commun (2026). https://doi.org/10.1038/s41467-026-77847-9 September 19, 2026. 

Overview

To elucidate the basis of cilta-cel’s efficacy, researchers analyzed CAR T cells from 87 patients with multiple myeloma (50 cilta-cel, 37 ide-cel) using flow cytometry and single-cell multi-omics. These findings suggest that the efficacy of cilta-cel is linked to an EF1α-driven GZMK⁺ transcriptional trajectory that supports both persistence and effector function. 

Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma

Source

Nicholas E. Bingham, Julie R. Boiko, Daniel C. Jones, Daniel Wong, Tiffany Khong, Sridurga Mithraprabhu, Kathleen S. Ensbey, Anna E. Elz, Evan W. Newell, Andrew Spencer, Geoffrey R. Hill; Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma. Blood Adv 2026; 10 (18): 6221-6235. doi: https://doi.org/10.1182/bloodadvances.2026020500 September 22, 2026. 

Overview

These findings reveal the spatial organization of extramedullary disease (EMD), highlighting niche substitution rather than niche independence, and identify clinically tractable microenvironmental niches and signaling. Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor outcomes because of aggressive disease kinetics and therapy resistance. 

Intratumoral microbiome signatures of multiple myeloma: a cross-sectional study

Source

Park, J., Hong, J., Kim, PJ. et al. Intratumoral microbiome signatures of multiple myeloma: a cross-sectional study. BMC Microbiol (2026). https://doi.org/10.1186/s12866-026-05672-7 September 23, 2026. 

Overview

The study aimed to profile the bone marrow microbiome in MM patients and subjects with normal bone marrow and to explore its biological plausibility through culture-based validation and in vitro functional assays. Bone marrow mononuclear cells from 50 MM patients and 25 controls were subjected to 16 S rRNA gene sequencing using a stringent contamination-control workflow. This study identified MM-associated alterations in the bone marrow microbial community, with culture and internalization data supporting the biological plausibility of a bone marrow-associated microbiota, warranting prospective investigation into its functional and clinical significance. 

MyeGPT: an AI agent for multiple myeloma

Source

Chang, J.G., Gout, A.M., Rodiger, J. et al. MyeGPT: an AI agent for multiple myeloma. BMC Med Inform Decis Mak (2026). https://doi.org/10.1186/s12911-026- 03862-x September 23, 2026. 

Overview

However, the complexity of this rich dataset-with 763 clinical parameters and summary data spread across > 20 filesimposes hurdles to clinician-researchers interested in making simple queries like “What percentage of patients relapse after VRD induction therapy?” or “Compare the overall survival of patients with high vs normal expression of NSD2”. MyeGPT demonstrates how agentic AI can eliminate the laborious scripting involved in analysing a large multi-omics dataset like CoMMpass. 

In vivo CAR T-cell therapy: determinants of response and durability

Source

Mohamed Abou-el-Enein; In vivo CAR T-cell therapy: determinants of response and durability. Blood Cancer Discov 2026; https://doi.org/10.1158/2643-3230.BCD- 26-0116 September 23, 2026. 

Overview

This review summarizes clinical data and defines determinants of response that could be optimized for durable translation. In vivo chimeric antigen receptor (CAR) T-cell therapy generates engineered lymphocytes inside the patient, bypassing leukapheresis, ex vivo manufacturing and, in many programs, lymphodepletion. 

Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model

Source

Akhlaghi, T., Nemirovsky, D., Maclachlan, K.H., Firestone, R.S., Korde, N., Mailankody, S., Lesokhin, A.M., Hassoun, H., Patel, D., Shah, U.A., Tan, C.R., Landau, H.J., Shah, G.L., Scordo, M., Simhal, A.K., Landgren, O., Giralt, S.A., Usmani, S.Z., Derkach, A. and Hultcrantz, M. (2026), Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model. HemaSphere, 10: e70473. https://doi.org/10.1002/hem3.70473 September 23, 2026. 

Overview

The study aimed to define evolving risk factors and integrate them with the 2/20/20 model to improve risk stratification. These findings support incorporating dynamic biomarkers into existing models to improve risk stratification and inform clinical decision-making in SMM. 

A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens

Source

L. Zhao, X. He, M. Deng, et al., “A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens,” Cancer Medicine 15, no. 9 (2026): e72314, https://doi.org/10.1002/cam4.72314. September 23, 2026. 

Overview

This study aims to assess the comparative efficacy and toxicity profiles of 3 versus 4 mg ixazomib in MM. Researchers performed a retrospective analysis of 207 MM patients undergoing ixazomib-based therapy across six medical centers. These findings suggest that initiating therapy with 3 mg ixazomib is both clinically viable and effective, potentially alleviating the economic burden for MM patients. 

Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy

Source

Kethidi, N., Pothukuchi, S., Aleman, A. et al. Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy. Nat Med (2026). https://doi.org/10.1038/s41591-026-04632-y September 23, 2026. 

Overview

Researchers define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)-a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Interferon and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial, and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. 

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

Source

Frigault MJ, Dhakal B, Jakubowiak AJ, Raje N, Banerjee K, Mu CJ, Hart KC, Shachar S, Andrews LP, Cheung LS, Griffin FM, Witter AR, Hyde M, Pham C, Gandra N, Shakya T, Rajan B, Cortesio C, Haile ST, Nowyhed H, Nair-Gupta P, Mitra P, Chan RJ, Kostic A, Heery CR, Rosenblatt J, Bishop MR. Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. N Engl J Med. 2026 Sep 24;395(12):1180-1192. doi: 10.1056/NEJMoa2603527. 

Overview

Anitocabtagene autoleucel (anito-cel), a B-cell maturation antigen (BCMA)-directed autologous chimeric antigen receptor (CAR) T-cell therapy with a synthetic D-domain binder (ddBCMA), may have efficacy in patients with relapsed or refractory multiple myeloma. In a phase 1 study, researchers evaluated the safety and efficacy of anito-cel (dose level 1, 100×106 CAR+ T cells; dose level 2, 300×106 CAR+ T cells) in patients with relapsed or refractory multiple myeloma who had received three or more lines of therapy previously or had triple-class refractory disease. Anito-cel therapy led to a high incidence of response among patients with heavily pretreated relapsed or refractory multiple myeloma. 

miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism

Source

Bai, Z., Luo, Q., & Zhao, S. (2026). miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism. Hematology, 31(1). https://doi.org/10.1080/16078454.2026.2722564 September 24, 2026. 

Overview

This study aimed to investigate the expression level, prognostic value, and biological function of miR-877-5p in MM. A total of 103 MM patients and 98 non-tumor controls were included in the study. miR-877- 5p expression level was verified by RT-qPCR, and its prognostic value was evaluated through Kaplan-Meier and the Cox regression model. The miR-877-5p/MAPK8 axis may represent a novel regulatory pathway involved in MM progression. 

Kidney Transplantation in Multiple Myeloma: Patient Selection, Timing, and Post-Transplant Challenges in the Modern Therapeutic Era

Source

Amir Shabaka, Teresa De Soto, Maria Ovidia López-Oliva, Javier Azores- Moreno, Carlos Jimenez-Martin, Kidney Transplantation in Multiple Myeloma: Patient Selection, Timing, and Post-Transplant Challenges in the Modern Therapeutic Era, Clinical Kidney Journal, 2026; sfag335, https://doi.org/10.1093/ckj/sfag335 September 24, 2026. 

Overview

This review summarizes current evidence on patient selection, optimal timing, and post-transplant management of kidney transplantation in MM. Available evidence, derived mainly from retrospective studies and small cohorts, suggests that patient and graft outcomes in carefully selected MM patients may approach those observed in other causes of ESKD. 

NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma

Source

Bo Hu, Jacob T. Edwards, Hardik Modi, Jim Gamez, Oscar Echeagaray, Kyle Hess, Yue Ren, Diana Anderson, Marta Larrayoz, Jinyi Zhu, Scott Johnson, Gauri Deb, Diana Jankeel, Preethi Janardhanan, Jim Leisten, Sophie Peng, Andy Christoforou, Nicholas Stong, Celia Fontanillo, Chad C. Bjorklund, Patrick R. Hagner, Anita K. Gandhi, Jose A. Martinez-Climent, Rama Krishna Narla, Antonia Lopez-Girona, Mark Rolfe, Neil Bence, Deborah S. Mortensen, Lynda Groocock; NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma. Blood 2026; 148 (13): 1694-1707. doi: https://doi.org/10.1182/blood.2025031998 September 24, 2026. 

Overview

Herein, researchers report the discovery of NSD2-ligand-directed degrader (NSD2- LDD), a cereblon-recruiting and PWWP1-mediated LDD that selectively and potently eliminates full-length and PWWP1 domain-containing NSD2 protein isoforms. Although the NSD2-LDD response is restricted to PWWP1-containing models, collectively this work validates NSD2 as a tractable dependency and supports the clinical development of NSD2 degradation as a novel, targeted therapeutic strategy in high-risk MM. 

Clinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma

Source

Beer, S.A., Cairns, D.A., Went, M. et al. Clinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01635-3 September 24, 2026. 

Overview

The study evaluated incidence, timing, and clinical risk factors in 4287 patients with newly diagnosed MM from the Myeloma-XI-trial; all received IMiD-based induction and 1412 were randomised to Lenalidomide (Len) maintenance. In addition to clinical risk factors, inherited variation at 6q15 may contribute to individual susceptibility. 

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

Source

Mian H, Faisal MS, Chen T, et al. Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer. 2026;e70614. doi:10.1002/cncr.70614 September 24, 2026. 

Overview

Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM). Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients receiving commercial cilta-cel from March 2022 to December 2023. Cilta-cel remains effective in frail RRMM, but frailty is associated with reduced survival and increased toxicity, supporting tailored CAR-T strategies. 

APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma

Source

Zhou L, Sun Y, Bi J, Zhao J, Xia Y, He J, Wang J, Pan L. APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma. Acta Pharm Sin B. 2026 Sep;16(9):5540-5552. doi: 10.1016/j.apsb.2026.02.001. Epub 2026 Feb 6. 

Overview

Researchers report the design of a dual-targeted ligand-drug conjugate (LDC) leveraging a proliferation-inducing ligand (APRIL), the natural ligand for both BCMA and transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI). These results establish a proof-of-concept for exploiting native ligands as dual-targeting agents in multitargeted therapeut treatment. 

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial

Source

Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K, Min CK, Oriol A, Moreira CCC, Quach H, Qiu L, Xia Z, Schjesvold F, Casas-Avilés I, Xu Y, Hungria V, Seval GC, Fang B, Kyriakou C, Prince HM, Zhuang J, Lin HC, Mateos MV, Špička I, Maiolino A, Vural F, Basu S, Dytfeld D, Fu C, Ho PJ, Joseph N, Low M, Pour L, Girnius S, Berdeja JG, Otero PR, Cheng Y, Amatangelo M, Hersey S, Kazanecki C, Weisskopf MB, Kyada MJ, Abad PC, Chu S, Morando J, Maciag P, Richardson PG, van de Donk NW; EXCALIBER-RRMM Investigators. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER- RRMM): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Sep 25:S1470-2045(26)00450-X. doi: 10.1016/S1470-2045(26)00450-X. Epub ahead of print. 

Overview

Researchers report the results of the primary analysis of MRD-negative complete response. EXCALIBER-RRMM is an ongoing, two-stage, open-label, randomised, controlled, phase 3 trial done at 211 hospital and community-based sites in 31 countries. Assessment of progression-free survival, the second dual primary endpoint, is ongoing. 

SF-DINO: Spatial-Frequency Adapted Foundation Model for Multiple Myeloma Diagnosis

Source

Ye, Z. et al. (2027). SF-DINO: Spatial-Frequency Adapted Foundation Model for Multiple Myeloma Diagnosis. In: Yang, G., et al. Medical Image Computing and Computer Assisted Intervention - MICCAI 2026. MICCAI 2026. Lecture Notes in Computer Science, vol 16886. Springer, Cham. https://doi.org/10.1007/978-3-032-38098-2_59 September 25, 2026. 

Overview

Microscopic analysis of bone marrow aspirate smears is a critical routine procedure for the initial screening and diagnosis of multiple myeloma (MM). Extensive experiments demonstrate that SF-DINO ("a spatial-frequency adapted foundation model that efficiently adapts DINOv3 for MM diagnosis") significantly outperforms six state-of-the-art methods, showing impressive generalization and establishing a new benchmark for automated, fine-grained MM diagnosis. 

Dual-targeting bispecific antibodies against extramedullary myeloma: A hypothesis-driven commentary

Source

Shiqiong Zhou, Qinghua Ke, Dual-targeting bispecific antibodies against extramedullary myeloma: A hypothesis-driven commentary, Translational Oncology, Volume 71, 2026, 102907, ISSN 1936-5233, https://doi.org/10.1016/j.tranon.2026.102907. September 2026. 

Overview

Note that cross-trial comparisons are shown for illustrative purposes only and should not be interpreted as evidence of superiority. (Table 1). Only then can researchers move from empirical combination to precision immunotherapy for this high-risk population.